Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of PF-06439535 vs Bevacizumab in Healthy Volunteers
NCT02031991Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2014
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bevacizumab-bvzr in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), glioblastoma (GBM) and 2 more (3 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Curve from Time Zero to end of dosing interval and 1 more. Started Jan 2014; status: completed.
02
Drugs
bevacizumab-bvzr
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)glioblastoma (GBM)renal cell carcinoma (RCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02031991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031991.